Mesothelioma Patients Live Longer After Aggressive Cancer Surgery

Aggressive pleurectomy/decortication surgery, while often recommended, will cause a significant decrease in pulmonary function with early-stage mesothelioma patients whose symptoms were previously minimal. More symptomatic patients with advanced disease will experience an improved quality of life and a preservation of their current pulmonary status after the same surgery. Those findings were reported in a study from the Department of Surgery, Division of Oncology at the University of Chicago Medical Center, raising questions about aggressive surgery for the early stages of mesothelioma. "Some of the results might be a little unexpected," renowned cardiothoracic surgeon Dr. Wickii Vigneswaran, told "They gave us something to look closer at. They didn't change our thinking." The study was published last month in the Annals of Thoracic Surgery. Performance Status Is Key The P/D surgery involves the removal of the pleural lining around the lungs, as well as any visible tumors on the lungs or surrounding areas. The surgery also often involves partial or complete resection of the diaphragm, which is rebuilt with prosthetics. The study included 36 mesothelioma patients at the University of Chicago Cancer Center, all of whom had the P/D surgery performed by Vigneswaran, one of the country's leading thoracic surgeons. He also is well known for his expertise in thoracic organ transplants. There were 17 patients with a performance status (PS) of 0 at ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Treatment & Doctors Source Type: news

Related Links:

Conclusions: A variant of opsoclonus-myoclonus-ataxia syndrome may occur following treatment with ipilimumab and nivolumab.
Source: Journal of Immunotherapy - Category: Allergy & Immunology Tags: Clinical Studies Source Type: research
Malignant pleural mesothelioma (MPM) is a rare tumor principally due to past exposure to asbestos, a carcinogenic natural mineral fiber that induces genomic and genetic alterations [1]. Lack of curative treatment due to resistance to anti-cancer therapies combined with tumor aggressiveness accounts for the poor prognosis associated to MPM. Despite the significant advances in oncotherapy, MPM is still a challenging cancer to treat [2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Authors: Funahashi S, Okazaki Y, Nishiyama T, Ohyoshi H, Yasui H, Nishida K, Matsui S, Toyokuni S Abstract Exposure to asbestos fiber is central to mesothelial carcinogenesis, for which iron overload in or near mesothelial cells is a key pathogenic mechanism. Alternatively, iron chelation therapy with deferasirox or regular phlebotomy was significantly preventive against crocidolite-induced mesothelial carcinogenesis in rats. However, the role of iron transporters during asbestos-induced carcinogenesis remains elusive. Here, we studied the role of divalent metal transporter 1 (DMT1; Slc11a2), which is a Fe(II) tran...
Source: Free Radical Research - Category: Research Tags: Free Radic Res Source Type: research
Malignant pleural mesothelioma (MPM) is an orphan disease that is difficult to treat using traditional chemotherapy, an approach which has been effective in other types of cancer. Most chemotherapeutics cause ...
Source: Journal of Translational Medicine - Category: Research Authors: Tags: Research Source Type: research
University of Leicester researchers soon will open the first molecularly stratified clinical trial for malignant mesothelioma with the hope of moving the future of treatment toward more personalization. The phase II trial in the United Kingdom is designed to match therapy with a patient’s specific genetic profile. “We’re trying to bring the right drug to the right patient at the right time,” Professor Dean Fennell, chair of thoracic medical oncology at Leicester and chief trial investigator, told “We need to find different treatments that work for different people. This is a step...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Abstract The receptor tyrosine kinase MET is frequently involved in malignant transformation and inhibiting its activity in MET-dependent cancers is associated with improved clinical outcomes. Emerging evidence also suggests that mitochondria play an essential role in tumorigenesis and Dynamin Related Protein (DRP1), a key component of the mitochondrial fission machinery, has emerged as an attractive therapeutic target. Here, we report that inhibiting MET activity with the tyrosine kinase inhibitor MGCD516 attenuates viability, migration, and invasion of non-small cell lung cancer (NSCLC) and malignant pleural mes...
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer related to asbestos exposure. The discovery of soluble biomarkers with diagnostic/prognostic and/or therapeutic properties would improve the...
Source: Molecular Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research
The U.S. Supreme Court on Wednesday will hear a product liability case filed by widows of Navy sailors seeking to recover damages for injuries related to asbestos exposure. It will be the third case on the docket for Justice Brett Kavanaugh, who was sworn in Saturday by Chief Justice John Roberts and retiring Justice Anthony Kennedy. The asbestos case, Air and Liquid Systems Corp. v. DeVries, involves a group of Navy sailors who developed mesothelioma from asbestos exposure. Defendants include Air &Liquid Systems and other large companies that manufactured equipment used by the Navy. Key facts about the case: Equ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ConclusionsReduction of postoperative complications after CRS –HIPEC is essential for optimal short- and long-term outcomes. For assessing total burden of postoperative complications per patient, CCI is superior to CDC and more sensitive for assessing surgery- and cancer-related outcomes after CRS–HIPEC.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
Malignant pleural mesothelioma (MPM) is a rare, highly lethal cancer occurring 4 times more frequently in men than in women, and for which historical exposure to asbestos is a well-documented etiological factor [1].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Cardiology | Cardiovascular & Thoracic Surgery | Chemotherapy | Environmental Health | Health | Heart | Lung Transplant | Mesothelioma | Palliative | Palliative Care | Study | Transplants